期刊文献+

加替沙星片人体药代动力学及生物等效性研究 被引量:3

Study on pharmacokinetics and bioequivalence of Gatifloxacin tablets in Chinese healthy volunteers
暂未订购
导出
摘要 目的:在中国健康成年男性志愿者中比较研究国产和进口加替沙星片剂的药代动力学参数,评估两者的生物等效性。方法:24名健康男性志愿者随机自身前后交叉给药,分别单剂口服国产和进口加替沙星片400mg。以HPLC测定血药浓度,应用DAS软件计算两者的药代动力学并考察其生物等效性。结果:受试者分别应用国产片剂(试验制剂)和进口片剂(参比制剂)400mg后,两药药-时曲线均符合二房室模型,主要药代动力学参数:Tmax分别为(0.99±0.41)h和(1.11±0.60)h;Cmax分别为(4.11±0.76)μg/mL和(3.89±0.54)μg/mL;t1/2β分别为(7.75±0.81)h和(7.39±0.92)h;AUC0-36h分别为(29.81±5.70)μg·mL-1·h和(30.77±4.40)μg·mL-1·h;AUC0-∞分别为(30.97±6.01)μg·mL-1·h和(31.85±4.58)μg·mL-1·h;国产片剂对于进口片剂的相对生物利用度F0-36h为(97.63±19.15)%。结论:国产与进口加替沙星片剂为生物等效制剂。 Objective:To study pharmacokinetics and bioequivalence of domestic and imported Gatifloxacin tablets in Chinese healthy volunteers.Methods:A single oral dose 400mg of domestic and imported Gatifloxacin tablets were given to 24 healthy volunteers in a randomized cross-over study.The concentrations of Gatifloxacin in human plasma were determined by HPLC and the pharmacokinetic parameters were calculated by DAS software.Results:The concentration-time curve of Gatifloxacin in plasma fit two compartment model after an oral single dose 400mg. The main pharmacokinetic parameters of domestic and imported tablet were as follows: Tmax were (0.99±0.41)h and (1.11 ±0.60)h, Cmax were (4.11±0.76)μg/mL and (3.89±0.54)μg/mL, t(1/2β) were (2.16±0.62)h and (2.31±0.50)h, AUC(0-36) were (29.81±5.70)μg·mL^-1·h and (30.77±4.40)μg·mL^-1·h, AUC(0-∞) were (30.97±6.01)μg·mL^-1·h and (31.85± 4.58)μg·mL^-1·h respectively.The relative bioavailability of Gatifloxacin was (97.63±19.15)%.Conclusion:The domestic and imported Gatifloxacin tablets were bioequivalent.
出处 《中国药物应用与监测》 CAS 2007年第4期18-21,共4页 Chinese Journal of Drug Application and Monitoring
关键词 加替沙星 高效液相色谱法 药代动力学 生物等效性 Gatifloxacin HPLC Pharmacokinetics Bioequivalence
  • 相关文献

参考文献6

二级参考文献35

  • 1赵树清,王金生.新型氟喹诺酮抗菌剂——AM—1155[J].中国医药情报,1996,2(4):249-252. 被引量:4
  • 2Hosaka M, Yasue T, Fukuda H, et al. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone[J].Antimicrob Agents Chemother, 1992,36:2108-2117
  • 3Hirai K, Yasue T, Hosaka M,et al. In vitro antibacterial activity of AM-1155[J]. Drugs,1993, 45(Suppl 3):182-183
  • 4Wakabayashi E, Mitsuhashi S. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone[J]. Antimicrob Agents Chemother, 1994,38: 594-601
  • 5Grasela DM. Clinical pharmacology of gatifloxacin, a new fluoroquinolone[J]. Clin Infect Dis, 2000,31(Supp1 2):S51-S58
  • 6Nakashima M, Uematsu T, Kosuge K, et al. Single and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans[J]. Antimicrob Agents Chemother,1995,39: 2635-2640
  • 7Brece J, Skuba K, Grasela DM. Safety and tolerability of gatifloxacin, an advanced-generation, 8-methoxy fluoroquinolone[J]. J Res Dis,1999,20(Suppl): S70-S76
  • 8Blondeau JM. Expanded activity and utility of the new fluoroquinolones: a review[J]. Clin Ther, 1999,21: 3-40
  • 9Lubasch A, Keller I, Borner K,et al. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin and moxifloxacin after single oral administration in healthy volunteers.J Anthmicrob Agents Chemother,2000,44(10) :2600
  • 10Naber CK, Steghafner M, Kingig-Schippers M, et al. Concentrations of gatifloxacin mesylate in plasma and urine and penetrition into prostatic and seminal fluid,ejaculate,and sperm cells after single oral administrations of 400 milligrams to volunteers. J Anthmicrob Agents Chemother,2001,45 (1) :293

共引文献100

同被引文献29

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部